CSS
NMTR

Cubist Systematic Strategies’s 9 Meters Biopharma NMTR Stock Holding History

Cubist Systematic Strategies’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30
Closed – – 4682
2022
Q1 		$0 Buy
+30
New +$410 ﹤0.01% 3904
2021
Q3 		– Sell
-10,429
Closed -$229K – 3256
2021
Q2 		$229K Buy
10,429
+8,294
+388% +$204K ﹤0.01% 2477
2021
Q1 		$50K Buy
+2,135
New +$65.6K ﹤0.01% 2735

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWM
Curi Wealth Management Raleigh, North Carolina $724M AUM 17.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Cubist Systematic Strategies's NMTR Position: Q2 2022 in Review

Cubist Systematic Strategies sold out of 9 Meters Biopharma (NMTR) in Q2 2022, closing a stake of 30 shares.

Cubist Systematic Strategies first reported a position in NMTR in Q1 2021 and held it in 3 quarters. The position peaked at $229K in Q2 2021. 88 funds tracked by Wall St. Rank hold NMTR as of Q2 2022.

  • Cubist Systematic Strategies reported no remaining 9 Meters Biopharma position as of Q2 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 30 9 Meters Biopharma shares in Q2 2022.
  • Cubist Systematic Strategies first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 3 quarters.
  • Cubist Systematic Strategies's 9 Meters Biopharma position peaked at $229K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2022.

Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.